Compare Inovio Pharmaceuticals Inc (INO) vs PepsiCo, Inc. (PEP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Inovio Pharmaceuticals Inc vs PepsiCo, Inc. — how do they compare? Inovio Pharmaceuticals Inc trades at $0.73 (market cap $78.55M), while PepsiCo, Inc. trades at $138.62 (market cap $188.91B). The key difference: PepsiCo, Inc. is far larger — about 2405× Inovio Pharmaceuticals Inc's market cap, and PepsiCo, Inc. pays a 4.28% dividend while Inovio Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| INO | PEP | |
|---|---|---|
Market Cap | $78.55M | $188.91B |
Sector | Health | Consumer Staples |
52-Week High | $2.87 | $170.44 |
52-Week Low | $0.66 | $134.95 |
Enterprise Value | $49.56M | $231.41B |
Dividend Yield | — | 4.28% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
PepsiCo (PEP) trades at $138.41, up 0.52% on the day, with a bearish technical signal from moving averages but neutral oscillators. The company reported revenue of $93.93B in 2025, with a net income margin of 10.78% and a P/E ratio of 18.14. Recent earnings have consistently beaten expectations, and analysts project a consensus price target of $158.79. News highlights include price cuts on snacks to address consumer pushback and the cessation of a festival sponsorship.
The outlook for PEP is cautiously optimistic, supported by strong profitability and dividend payments, but faces risks from competitive pressures and price sensitivity. Upside potential exists if North American performance improves as anticipated in upcoming earnings. Investor sentiment is mixed, with a majority of analysts recommending Hold, reflecting balanced growth prospects against near-term challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Inovio Pharmaceuticals Inc
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →About PepsiCo, Inc.
PepsiCo is one of the largest food and beverage companies globally. It makes, markets, and sells a slew of brands across the beverage and snack categories, including Pepsi, Mountain Dew, Gatorade, Doritos, Lays, and Ruffles. The firm uses a largely integrated go-to-market model, though it does leverage third-party bottlers, contract manufacturers, and distributors in certain markets. In addition to company-owned trademarks, Pepsi manufactures and distributes other brands through partnerships and joint ventures with companies such as Starbucks. The firm segments its operations into five primary geographies, with North America (comprising Frito-Lay North America, Quaker Foods North America, and North America beverages) constituting around 60% of consolidated revenue.
Read more on PEP →
